• news.cision.com/
  • C-RAD/
  • C-RAD has signed an agreement with Brigham and Women´s Hospital, Boston, USA.
English

C-RAD has signed an agreement with Brigham and Women´s Hospital, Boston, USA.

Report this content 
Press release 2009-03-19 


C-RAD has signed an agreement with Brigham and Women´s Hospital, Boston, USA. 

C-RAD AB with its three fully owned subsidiaries develops new and innovative
solutions for the use in advanced radiation therapy. The subsidiary C-RAD
Imaging has signed an agreement for clinical evaluation of its unique GEMini
technology with Brigham and Women´s Hospital, an affiliate of Harvard Medical
School in Boston. 

The GEMiniTM family of image detector panels is primarily designed for use in
radiation therapy but the panels can also be used in industrial radiography
systems. The market potential for C-RAD Imaging's GEM technology is at least
150 MUSD per year. GEMiniTM products represent world class performance and
comprise state of the art technology including new unique patented inventions.
These new inventions enable superior image quality and real time detection
combined with lower cost of ownership. 
The evaluation of the GEMini detector will be managed by Dr. Piotr Zygmanski,
Staff Physicist at Brigham and Women's Hospital (BWH) and Instructor in
Radiation Oncology at Harvard Medical School. The detector will initially be
evaluated as a so called EPID in radiation therapy followed by a proposal to
develop new functionalities to the system. The evaluation process is planned to
start at the beginning of the second quarter of 2009. 

Erik Hedlund, CEO, C-RAD AB:
”The C-RAD Imaging group is encouraged by the great interest for the GEMini
technology and its potential for use in radiation therapy expressed by Dr.
Zygmanski at the Department of Radiation Oncology, Brigham and Women´s Hospital
at Harvard. We are looking forward to a close cooperation with the Department
and are excited about the possibilities to add new functionalities to the
system.“ 

Piotr Zygmanski, PhD, Staff Physicist at BWH and Instructor in Radiation
Oncology, Harvard Medical School confirmed that he is planning to evaluate
GEMini for imaging of patient anatomy and verification of deposited dose. 

For further information: 
Erik Hedlund, CEO C-RAD AB, Telephone 018- 666931, E-mail: erik.hedlund@c-rad.se

Documents & Links